Bortezomib Increased Vascular Permeability by Decreasing Cell–Cell Junction Molecules in Human Pulmonary Microvascular Endothelial Cells
Authors:
- Taichi MatsumotoTMTaichi Matsumoto
- Junichi MatsumotoJMJunichi Matsumoto
- Yuka MatsushitaYMYuka Matsushita
- Moeno ArimuraMAMoeno Arimura
- Kentaro AonoKAKentaro Aono
- Mikiko AokiMAMikiko Aoki
- Kazuki TeradaKTKazuki Terada
- Masayoshi MoriMMMasayoshi Mori
- Yutaka HaramakiYHYutaka Haramaki
- Takuya ImatohTITakuya Imatoh
- Atsushi YamauchiAYAtsushi Yamauchi
- Keisuke MigitaKMKeisuke Migita
Open Access
- 29 June 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 10842
Abstract
Bortezomib (BTZ), a chemotherapeutic drug used to treat multiple myeloma, induces life-threatening side effects, including severe pulmonary toxicity. However, the mechanisms underlying these effects remain unclear. The objectives of this study were to (1) investigate whether BTZ influences vascular permeability and (2) clarify the effect of BTZ on the expression of molecules associated with cell–cell junctions using human pulmonary microvascular endothelial cells in vitro. Clinically relevant concentrations of BTZ induced limited cytotoxicity and increased the permeability of human pulmonary microvascular endothelial cell monolayers. BTZ decreased the protein expression of claudin-5, occludin, and VE-cadherin but not that of ZO-1 and β-catenin. Additionally, BTZ decreased the mRNA expression of claudin-5, occludin, ZO-1, VE-cadherin, and β-catenin. Our results suggest that BTZ increases the vascular permeability of the pulmonary microvascular endothelium by downregulating cell–cell junction molecules, particularly claudin-5, occludin, and VE-cadherin.Keywords
Funding Information
- Japan Society for the Promotion of Science (21K06703, 226005)
- Fukuoka University (21K06703, 226005)
This publication has 38 references indexed in Scilit:
- In Vitro Blood-Brain Barrier Models Using Brain Capillary Endothelial Cells Isolated from Neonatal and Adult Rats Retain Age-Related Barrier PropertiesPLOS ONE, 2013
- Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyCancer Chemotherapy and Pharmacology, 2011
- Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transitionCancer Science, 2010
- Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signalingBlood, 2009
- Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myelomaHaematologica, 2008
- VE-cadherin and β-catenin binding dynamics during histamine-induced endothelial hyperpermeabilityAmerican Journal of Physiology-Cell Physiology, 2008
- Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drugAmerican Journal of Hematology, 2007
- Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasoneLeukemia & Lymphoma, 2007
- Severe pulmonary complication after bortezomib treatment for multiple myelomaBlood, 2006
- Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myelomaBlood, 2006